178 related articles for article (PubMed ID: 24421288)
1. Cardiac hypoxia imaging: second-generation analogues of 64Cu-ATSM.
Handley MG; Medina RA; Mariotti E; Kenny GD; Shaw KP; Yan R; Eykyn TR; Blower PJ; Southworth R
J Nucl Med; 2014 Mar; 55(3):488-94. PubMed ID: 24421288
[TBL] [Abstract][Full Text] [Related]
2. 64Cu-CTS: A Promising Radiopharmaceutical for the Identification of Low-Grade Cardiac Hypoxia by PET.
Medina RA; Mariotti E; Pavlovic D; Shaw KP; Eykyn TR; Blower PJ; Southworth R
J Nucl Med; 2015 Jun; 56(6):921-6. PubMed ID: 25883129
[TBL] [Abstract][Full Text] [Related]
3. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
4. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
6. Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.
Bonnitcha PD; Bayly SR; Theobald MB; Betts HM; Lewis JS; Dilworth JR
J Inorg Biochem; 2010 Feb; 104(2):126-35. PubMed ID: 19932509
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.
Lewis JS; McCarthy DW; McCarthy TJ; Fujibayashi Y; Welch MJ
J Nucl Med; 1999 Jan; 40(1):177-83. PubMed ID: 9935074
[TBL] [Abstract][Full Text] [Related]
8. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone).
Lewis JS; Herrero P; Sharp TL; Engelbach JA; Fujibayashi Y; Laforest R; Kovacs A; Gropler RJ; Welch MJ
J Nucl Med; 2002 Nov; 43(11):1557-69. PubMed ID: 12411560
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluations of a hydrophilic 64Cu-bis(thiosemicarbazonato)-glucose conjugate for hypoxia imaging.
Bayly SR; King RC; Honess DJ; Barnard PJ; Betts HM; Holland JP; Hueting R; Bonnitcha PD; Dilworth JR; Aigbirhio FI; Christlieb M
J Nucl Med; 2008 Nov; 49(11):1862-8. PubMed ID: 18927340
[TBL] [Abstract][Full Text] [Related]
10. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
11. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential.
Fujibayashi Y; Taniuchi H; Yonekura Y; Ohtani H; Konishi J; Yokoyama A
J Nucl Med; 1997 Jul; 38(7):1155-60. PubMed ID: 9225812
[TBL] [Abstract][Full Text] [Related]
12. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of the retention of 64Cu-ATSM in cardiac myocytes using a novel incubation chamber for screening hypoxia-dependent radiotracers.
Handley MG; Medina RA; Paul RL; Blower PJ; Southworth R
Nucl Med Commun; 2013 Oct; 34(10):1015-22. PubMed ID: 23872986
[TBL] [Abstract][Full Text] [Related]
14. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines.
Vāvere AL; Lewis JS
Nucl Med Biol; 2008 Apr; 35(3):273-9. PubMed ID: 18355682
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.
Carlin S; Zhang H; Reese M; Ramos NN; Chen Q; Ricketts SA
J Nucl Med; 2014 Mar; 55(3):515-21. PubMed ID: 24491409
[TBL] [Abstract][Full Text] [Related]
16. Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.
Liu J; Hajibeigi A; Ren G; Lin M; Siyambalapitiyage W; Liu Z; Simpson E; Parkey RW; Sun X; Oz OK
J Nucl Med; 2009 Aug; 50(8):1332-9. PubMed ID: 19617332
[TBL] [Abstract][Full Text] [Related]
17. Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.
McCall KC; Humm JL; Bartlett R; Reese M; Carlin S
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e393-9. PubMed ID: 22727887
[TBL] [Abstract][Full Text] [Related]
18. Cellular Uptake of the ATSM-Cu(II) Complex under Hypoxic Conditions.
Walke GR; Meron S; Shenberger Y; Gevorkyan-Airapetov L; Ruthstein S
ChemistryOpen; 2021 Apr; 10(4):486-492. PubMed ID: 33908707
[TBL] [Abstract][Full Text] [Related]
19. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo.
Hueting R; Kersemans V; Cornelissen B; Tredwell M; Hussien K; Christlieb M; Gee AD; Passchier J; Smart SC; Dilworth JR; Gouverneur V; Muschel RJ
J Nucl Med; 2014 Jan; 55(1):128-34. PubMed ID: 24337603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
